For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

But Stuart Orkin, MD, the Boston Children's hematologist whose work led the way to Casgevy, wants to go even further. "The editing therapy is a wonderful achievement, but only a small fraction of ...

The Food and Drug Administration approval in December 2023 of the first CRISPR therapeutic, Casgevy to treat sickle cell, came 11 years after the discovery of the revolutionary gene-editing technology ...

People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...

However, he added: "We remain acutely aware that not everyone with sickle cell will be eligible for the potentially ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY ... industry's top places to work, including ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...